Herpes simplex virus-based vectors for the treatment of cancer and neurodegenerative disease

Current Opinion in Molecular Therapeutics

Volumn 7, Issue 5, 2005, Pages 415-418

  Latchman, David S ^a,b  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cancer; Herpes simplex virus; Neurodegenerative disease; Oncolytic virus; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; AMINO ACID DECARBOXYLASE; ANTINEOPLASTIC AGENT; ENDOSTATIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 27; KAINIC ACID; ONCOLYTIC VIRUS; RIBONUCLEOTIDE REDUCTASE; SUPEROXIDE DISMUTASE; THYMIDINE KINASE; TUMOR ANTIGEN; TYROSINE 3 MONOOXYGENASE; VIRUS ONCOLYSATE; VIRUS VECTOR;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER THERAPY; CELL CULTURE; CELL DIVISION; CLINICAL TRIAL; DEGENERATIVE DISEASE; DISEASE MODEL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; EPILEPSY; GENE MUTATION; GENETIC ENGINEERING; GLIOBLASTOMA; HERPES SIMPLEX VIRUS; HUMAN; MOTOR NEURON DISEASE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; REVIEW; RISK ASSESSMENT; TRANSGENICS; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE; VIRUS REPLICATION;

GENE THERAPY; GENETIC VECTORS; HUMANS; NEURODEGENERATIVE DISEASES; ONCOLYTIC VIRUSES; PARKINSON DISEASE; SIMPLEXVIRUS;

ANIMALIA; SIMPLEXVIRUS;

EID: 27144474495     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Latchman DS: Herpes simplex virus vectors for Parkinson's disease. Int Rev Neurobiol (2003) 55:223-241.
2. Glorioso JC, Fink DJ: Herpes vector-mediated gene transfer in treatment of diseases of the nervous system. Annu Rev Microbiol (2004) 58:253-271.
3. Goins WF, Wolfe D, Krisky DM, Bai Q, Burton EA, Fink DJ, Glorioso JC: Delivery using herpes simplex virus: An overview. Methods Mol Biol (2004) 246:257-299.
4. Perez MCP, Hunt SP, Coffin RS, Palmer JA: Comparative analysis of genomic HSV vectors for gene delivery to motor neurons following peripheral inoculation in vivo. Gene Ther (2004) 11(13):1023-1032.
5. Akbar MT, Lundberg AMC, Liu K, Vidyadaran S, Wells KE, Dolatshad H, Wynn S, Wells DJ, Latchman DS, de Belleroche J: The neuroprotective effects of heat shock protein 27 overexpression in transgenic animals against kainate-induced seizures and hippocampal cell death. J Biol Chem (2003) 278(22):19956-19965.
6. Kalwy S, Akbar MT, Coffin RS, de Belleroche J, Latchman DS: Heat shock protein 27 delivered via a herpes simplex virus vector can protect neurones of the hippocampus against kainic acid-induced cell loss. Mol Brain Res (2003) 111(1-2):91-103.
7. Zourlidou A, Payne Smith MD, Latchman DS: Hsp27 but not Hsp70 has a potent protective effect against α-synuclein-induced call death in mammalian neuronal calls. J Neurochem (2004) 88(6):1439-1448.
8. Patel YJK, Payne-Smith MD, de Belleroche J, Latchman DS: Hsp27 and Hsp70 administered in combination have a potent protective effect against FALS-associated SOD1-mutant-induced cell death in mammalian neuronal cells. Mol Brain Res (2005) 134(2):256-274.
9. Burton EA, Glorioso JC, Fink DJ: Gene therapy progress and prospects: Parkinson's disease. Gene Ther (2003) 10(20):1721-1727.
10. Fink DJ, Glorioso J, Mata M: Therapeutic gene transfer with herpes-based vectors: Studies in Parkinson's disease and motor nerve regeneration. Exp Neurol (2003) 184(Suppl 1):S19-S24.
11. Sun M, Zhang GR, Kong L, Holmes C, Wang X, Zhang W, Goldstein DS, Geller AI: Correction of a rat model of Parkinson's disease by coexpression of tyrosine hydroxylase and aromatic amino acid decarboxylase from a helper virus-free herpes simplex virus type 1 vector. Hum Gene Thar (2003) 14(5):415-424.
12. Monville C, Torres E, Thomas E, Scarpini CG, Muhith J, Lewis J, Finn J, Smith C, Cai S, Efstathiou S, Howard K, Dunnett SB: HSV vector-delivery of GDNF in a rat model of PD: Partial efficacy obscured by vector toxicity. Brain Res (2004) 1024(1-2):1-15.
13. Harvey BK, Chang CF, Chiang YH, Bowers WJ, Morales M, Hoffer BJ, Wang Y, Federoff HJ: HSV amplicon delivery of glial cell line-derived neurotrophic factor is neuroprotective against ischemic injury. Exp Neurol (2003) 183(1):47-55.
14. Hao S, Mata M, Wolfe D, Huang S, Glorioso JC, Fink DJ: HSV-mediated gene transfer of the glial cell-derived neurotrophic factor provides an antiallodynic effect on neuropathic pain. Mol Ther (2003) 8(3):367-375.
15. Lilley CE, Groutsi F, Han Z, Palmer JA, Anderson PN, Latchman DS, Coffin RS: Multiple immediate-early gene-deficient herpes simplex virus vectors allowing efficient gene delivery to neurons in culture and widespread gene delivery to the central nervous system in vivo. J Virol (2001) 75(9):4343-4356.
16. Puskovic V, Wolfe D, Goss J, Huang S, Mata M, Glorioso JC, Fink DJ: Prolonged biologically active transgene expression driven by HSV LAP2 in brain in vivo. Mol Ther (2004) 10(1):67-75.
17. Varghese S, Rabkin SD: Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther (2002) 9(12):967-978.
18. Hu JC, Coffin RS: Oncolytic herpes simplex virus for tumor therapy. Int Rev Neurobiol (2003) 55:165-184.
19. Yu Z, Eisenberg DP, Singh B, Shah JP, Fong Y, Wong RJ: Treatment of aggressive thyroid cancer with an oncolytic herpes virus. Int J Cancer (2004) 112(3):525-532.
20. Nawa A, Nozawa N, Goshima F, Nagasaka T, Kikkawa F, Niwa Y, Nakanishi T, Kuzuya K, Nishiyama Y: Oncolytic viral therapy for human ovarian cancer using a novel replication-competent herpes simplex virus type I mutant in a mouse model. Gynecol Oncol (2003) 91(1):81-88.
21. Stanziale SF, Stiles BM, Bhargava A, Kerns SA, Kalakonda N, Fong Y: Oncolytic herpes simplex virus-1 mutant expressing green fluorescent protein can detect and treat peritoneal cancer. Hum Gene Ther (2004) 15(6):609-618.
22. Kamiyama H, Kurosaki K, Kurimoto M, Katagiri T, Nakamura Y, Kurokawa M, Sato H, Endo S, Shiraki K: Herpes simplex virus-induced, death receptor-dependent apoptosis and regression of transplanted human cancers. Cancer Sci (2004) 95(12):990-998.
23. Thomas DL, Fraser NW: HSV-1 therapy of primary tumors reduces the number of metastases in an immune-competent model of metastatic breast cancer. Mol Ther (2003) 8(4):543-551.
24. Lou E: Oncolytic herpes viruses as a potential mechanism for cancer therapy. Acta Oncol (2003) 42(7):660-671.
25. Harrow S, Papanastassiou V, Harland J, Mabbs R, Petty R, Fraser M, Hadley D, Patterson J, Brown SM, Rampling R: HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: Safety data and long-term survival. Gene Ther (2004) 11(22):1648-1658.
26. Post DE, Fulci G, Chiocca EA, Van Meir EG: Replicative oncolytic herpes simplex viruses in combination cancer therapies. Curr Gene Ther (2004) 4(1):41-51.
27. Mullen JT, Donahue JM, Chandrasekhar S, Yoon SS, Liu W, Ellis LM, Nakamura H, Kasuya H, Pawlik TM, Tanabe KK: Oncolysis by viral replication and inhibition of angiogenesis by a replication-conditional herpes simplex virus that expresses mouse endostatin. Cancer (2004) 101(4):869-877.
28. Nakamori M, Fu X, Pettaway CA, Zhang X: Potent antitumor activity after systemic delivery of a doubly fusogenic oncolytic herpes simplex virus against metastatic prostate cancer. Prostate (2004) 60(1):53-60.
29. Liu BL, Robinson M, Han Z-Q, Branston RH, English C, Reay P, McGrath Y, Thomas SK, Thornton M, Bullock P, Love CA, Coffin RS: ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther (2003) 10(4):292-303.
30. Relph K, Harrington K, Pandha H: Recent developments and current status of gene therapy using viral vectors in the United Kingdom. Br Med J (2004) 329(7470):839-842.
31. Samady L, Costigliola E, MacCormac L, McGrath Y, Cleverley S, Lilley CE, Smith J, Latchman DS, Chain B, Coffin RS: Deletion of the virion host shutoff protein (VHS) from herpes simplex virus (HSV) relieves the viral block to dendritic cell activation: Potential of VHS-HSV vectors for dendritic cell mediated immunotherapy. J Virol (2003) 77(6):3768-3776.
32. Bennett JJ, Adusumilli P, Petrowsky H, Burt BM, Roberts G, Delman KA, Zager JS, Chou TC, Fong Y: Up-reguladon of GADD34 mediates the synergistic anticancer activity of mitomycin C and a γ134.5 deleted oncolytic herpes virus (G207). FASEB J (2004) 18(9):1001-1003.